Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2017

01-08-2017 | Head and Neck Oncology

Model to Predict Cause-Specific Mortality in Patients with Head and Neck Adenoid Cystic Carcinoma: A Competing Risk Analysis

Authors: Matin Imanguli, MD, DDS, Baran D. Sumer, MD

Published in: Annals of Surgical Oncology | Issue 8/2017

Login to get access

Excerpt

Adenoid cystic carcinoma is a relatively uncommon malignancy constituting approximately 1% of head and neck malignancies and approximately 10% of salivary gland tumors.1 It is the most common malignant tumor of the minor salivary glands and can occur throughout the head and neck, including in the major and minor salivary glands, nasal cavities and lacrimal glands. It is characterized by an indolent growth pattern with lymph node metastasis being uncommon, occurring only in approximately 10–15% of cases. Yet, despite this indolent biological behavior, it is classified as a high grade malignancy, primarily due to its propensity to recur locally despite clear surgical margins. …
Literature
1.
Coca-Pelaz A, Rodrigo JP, Bradley PJ et al. Adenoid cystic carcinoma of the head and neck–An update. Oral Oncol 2015; 51: 652–661.CrossRefPubMed
2.
Schroeder U, Groppe D, Mueller RP, Guntinas-Lichius O. Parotid cancer: Impact of changes from the 1997 to the 2002 American Joint Committee on Cancer classification on outcome prediction. Cancer 2008; 113: 758–764.CrossRefPubMed
3.
Roesink JM, Moerland MA, Hoekstra A et al. Scintigraphic assessment of early and late parotid gland function after radiotherapy for head-and-neck cancer: a prospective study of dose-volume response relationships. Int J Radiat Oncol Biol Phys 2004; 58: 1451–1460.CrossRefPubMed
4.
Garden AS, el-Naggar AK, Morrison WH et al. (1997) Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 37: 79–85.CrossRefPubMed
5.
Armstrong JG, Harrison LB, Spiro RH et al. Observations on the natural history and treatment of recurrent major salivary gland cancer. J Surg Oncol 1990; 44: 138–141.CrossRefPubMed
6.
Harrison LB, Armstrong JG, Spiro RH et al. Postoperative radiation therapy for major salivary gland malignancies. J Surg Oncol 1990; 45: 52–55.CrossRefPubMed
7.
Dillon PM, Chakraborty S, Moskaluk CA et al. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head Neck 2016; 38: 620–627.CrossRefPubMed
8.
Ellington CL, Goodman M, Kono SA et al. Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. Cancer 2012; 118: 4444–4451.CrossRefPubMed
9.
Ciccolallo L, Licitra L, Cantu G et al. Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncol 2009; 45: 669–674.CrossRefPubMed
10.
Bjorndal K, Krogdahl A, Therkildsen MH et al. Salivary adenoid cystic carcinoma in Denmark 1990-2005: Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 2015; 51: 1138–1142.CrossRefPubMed
11.
Ganly I, Amit M, Kou L et al. Nomograms for predicting survival and recurrence in patients with adenoid cystic carcinoma. An international collaborative study. Eur J Cancer 2015; 51: 2768–2776.CrossRefPubMedPubMedCentral
Metadata
Title
Model to Predict Cause-Specific Mortality in Patients with Head and Neck Adenoid Cystic Carcinoma: A Competing Risk Analysis
Authors
Matin Imanguli, MD, DDS
Baran D. Sumer, MD
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-5862-y

Other articles of this Issue 8/2017

Annals of Surgical Oncology 8/2017 Go to the issue

Gastrointestinal Oncology

Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy

Hepatobiliary Tumors

Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma

Hepatobiliary Tumors

Laparoscopic Parenchymal-Sparing Liver Resections Using the Intrahepatic Glissonian Approach

Gastrointestinal Oncology

Intragastric Single-Incision Laparoscopic Surgery for Gastric Leiomyoma: A Stepwise Approach

Pancreatic Tumors

Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials

Thoracic Oncology

Practical Surgical Techniques for Lymphadenectomy Along the Right Recurrent Laryngeal Nerve During Thoracoscopic Esophagectomy in the Prone Position